DIAMEDICA THERAPEUTICS INC (DMAC) competitors & alternatives
Health Care · NASDAQ
DIAMEDICA THERAPEUTICS INC (DMAC)'s top competitors and alternatives — its most similar public companies — include Medtronic (MDT), Stryker Corporation (SYK), LEXEO THERAPEUTICS INC (LXEO), BIOAGE LABS INC (BIOA), Tenaya Therapeutics, Inc. (TNYA), ASTRAZENECA PLC (AZN), ANNEXON INC (ANNX), Penumbra, Inc. (PEN), Encompass Health (EHC), NEUROGENE INC (NGNE), LEMAITRE VASCULAR INC (LMAT) and LEXICON PHARMACEUTICALS INC (LXRX). These are DIAMEDICA THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top DMAC competitors & alternatives
-
MedtronicMDTHealth Care
Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain,…
$81.89 (as of 2026-07-22) · market cap $105.1B
-
Stryker CorporationSYKHealth Care
A diversified medical technology leader offering surgical equipment, orthopedic robotics, and minimally invasive neurovascular products that collectively serve…
$309.24 (as of 2026-07-22) · market cap $119.6B
-
LEXEO THERAPEUTICS INCLXEOHealth Care
Lexeo is a clinical-stage genetic medicine company developing gene therapies targeting the genetic root causes of rare cardiovascular diseases like Friedreich…
$4.87 (as of 2026-07-22) · market cap $365M
-
BIOAGE LABS INCBIOAHealth Care
Clinical-stage biotech targeting aging biology to develop novel small-molecule therapeutics for metabolic and cardiovascular diseases, led by brain-penetrant…
$21.94 (as of 2026-07-22) · market cap $975M
-
Tenaya Therapeutics, Inc.TNYAHealth Care
Tenaya Therapeutics is a clinical-stage biopharmaceutical company leveraging gene therapy and small molecule platforms to develop curative, precision-medicine…
$0.79 (as of 2026-07-22) · market cap $171M
-
ASTRAZENECA PLCAZN
Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
$169.73 (as of 2026-07-22) · market cap $193.7B
-
ANNEXON INCANNXHealth Care
Annexon is a clinical-stage biotechnology company developing C1q-inhibitor therapies to treat neurodegenerative and autoimmune diseases driven by the classical…
$5.23 (as of 2026-07-22) · market cap $857M
-
Penumbra, Inc.PENHealth Care
The world's leading mechanical thrombectomy company enabling rapid, minimally invasive blood clot removal across ischemic stroke, pulmonary embolism, and limb…
$316.50 (as of 2026-07-22) · market cap $12.4B
-
Encompass HealthEHCHealth Care
The nation's largest inpatient rehabilitation hospital operator, helping patients recover functional independence after major injuries and illnesses through…
$111.02 (as of 2026-07-22) · market cap $11.0B
-
NEUROGENE INCNGNEHealth Care
Neurogene is a clinical-stage gene therapy company utilizing proprietary transgene regulation technology to develop treatments for rare, devastating…
$36.11 (as of 2026-07-22) · market cap $721M
-
LEMAITRE VASCULAR INCLMATHealth Care
LeMaitre Vascular develops specialized medical devices and tissue-based solutions for vascular and cardiovascular surgery, targeting an aging population with…
$98.81 (as of 2026-07-22) · market cap $2.3B
-
LEXICON PHARMACEUTICALS INCLXRXHealth Care
An early-stage commercial biopharmaceutical company with a gene-discovery platform advancing cardiovascular and metabolic therapies, headlined by…
$2.25 (as of 2026-07-22) · market cap $1.0B
Not quite? Describe exactly what you want →
Peers are DIAMEDICA THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: DIAMEDICA THERAPEUTICS INC (DMAC).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.